Mention377984
Download triples| rdf:type | qkg:Mention |
| so:text | Even when the FDA agrees to expanded access, pharmaceutical companies are often reluctant to give terminal patients a drug that is still in development. If patients die from organ failure related to their disease, the FDA may require additional studies from the manufacturer to make sure that the death was not hurried along by the drug. Naturally, the extra studies increase the development timeline and overall cost. (en) |
| so:isPartOf | https://en.wikiquote.org/wiki/Mary_Ruwart |
| so:description | Death by Regulation: How We Were Robbed of a Golden Age of Health and How We Can Reclaim It, (2018) (en) |
| qkg:hasContext | qkg:Context186003 |
| Property | Object |
|---|
Triples where Mention377984 is the object (without rdf:type)
| qkg:Quotation357412 | qkg:hasMention |
| Subject | Property |
|---|
